Shellbell
I believe that the patent application I referred to covers both CellPryme-M and CellPryme- A.
I’ll try to explain my thinking by looking at a few of the patent claims
Culturing cells (be they T-cells, dendritic cells, natural killer cells, myeloid cells, macrophages or a combination thereof) in a medium containing an AKT inhibitor and/or an inhibitor of a PH domain protein – that’s CellPryme-M.
- A method of modifying an immune response in a subject, the method comprising administering to the subject a population of immune cells, wherein the immune cells were produced using a method comprising culturing immune cells in medium comprising an AKT inhibitor and/or an inhibitor of a PH domain protein, preferably wherein the immune cells are T-cells, dendritic cells, natural killer cells, myeloid cells, macrophages or a combination thereof.
Administering an AKT inhibitor and/or an inhibitor of a PH domain protein at least 18 hours before administering Car-T cells – that’s CellPryme-A
- A method of modifying an immune response in a subject, preferably a T-cell response, the method comprising:a) administering to the subject an AKT inhibitor and/or an inhibitor of a PH domain protein, and b) at least about 18 hours after step a) administering to the subject a population of immune cells, preferably comprising T-cells comprising a chimeric antigen receptor (CAR-T-cells).
Administering an AKT inhibitor and/or an inhibitor of a PH domain protein in addition to administering dendritic or NK cells – that’s CellPryme-A
- A method of modifying a dendritic cell and/or natural killer cell response in a subject, the method comprising; a) administering to the subject an AKT inhibitor and/or an inhibitor of a PH domain protein, and b) administering to the subject a population of immune cells comprising dendritic cell and/or natural killer cells.
Administering an AKT inhibitor and/or an inhibitor of a PH domain protein 18-72 hours prior to administering CAR-T, dendritic or NK cells – that’s CellPryme-A.
- The method of claim 3 or claim 4, wherein the population of immune cells are administered between about 18 hours and about 72 hours after the AKT inhibitor and/or an inhibitor of a PH domain protein.
As I said, the preference seems to be for administering CellPryme-A at least 18 hours prior to administering cell therapy; hence, use of CellPryme-A as a neoadjuvant. There is then a choice to use Cellpryme-M enhanced cell therapy if you want even more bang for your buck.
I don’t know exactly what FDA regulatory requirements are for either adjuvants or neoadjuvants but given the company statement
CP-A requires new trial protocols and changes to reg packages to be used in combination with other CAR-T therapies. This requires significant effort & investment
I think you can safely assume it’s neither fast nor simple!
- Forums
- ASX - By Stock
- PTX
- Pitt St Research Report...
Pitt St Research Report..., page-15
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.1¢ |
Change
0.001(1.25%) |
Mkt cap ! $32.61M |
Open | High | Low | Value | Volume |
4.0¢ | 4.1¢ | 4.0¢ | $34.57K | 860.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 99935 | 4.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.1¢ | 458172 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 99935 | 0.040 |
4 | 433434 | 0.039 |
10 | 1290788 | 0.038 |
3 | 130515 | 0.037 |
5 | 429500 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.041 | 458172 | 3 |
0.042 | 200000 | 1 |
0.043 | 347971 | 3 |
0.044 | 210000 | 2 |
0.045 | 407000 | 3 |
Last trade - 15.57pm 21/06/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online